Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau;Consorcio Centro de Investigación Biomédica en Red M.P.;Universitat Autònoma de Barcelona
发明人:
申请号：
EP18382527.2
公开号：
EP3597193A1
申请日:
2018.07.16
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention provides the afatinib or a pharmaceutically salt thereof for use in the treatment and/or prevention of a cancer in a patient suffering from a disease caused by a defect in DNA damage repair mechanism.Surprisingly, when afatinib was administered to FA cells, it was confirmed that there was a therapeutic anti-cancer effect without any toxic side-effect on DNA.
